ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Soligenix Announces SGX301Study Continues to Demonstrate Positive Benefits americanpharmaceuticalreview
October 29, 2020Soligenix announced continued optional treatment with SGX301 (synthetic hypericin) across all lesions during the compassionate use, safety portion of the trial (Cycle 3), for a total of 6 months in the study, continued to significantly improve responses..
Pharma Sources Insight January 2025
